Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer
The results from the renal cell carcinoma (RCC) group of [...]
Tyrosine kinase inhibitors for kidney cancer: Past, present and future
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA
The US Food and Drug Administration (FDA) have granted Breakthrough [...]
Sequencing of treatments for advanced kidney cancer remains uncertain
There are now a number of licensed drug options available [...]
Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer
Fantastic news for people with advanced kidney cancer: the lenvatinib [...]
The evolving management of advanced renal cell carcinoma
This article, published in UroToday this week, is a nice summary [...]
European Society of Medical Oncology (ESMO) highlights from the IKCC
The International Kidney Cancer Coalition (IKCC) had a booth at [...]
Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer
Interim results from Study 111, a phase Ib/II clinical trial [...]
European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer
The European Commission has approved Kisplyx (lenvatinib) for the treatment [...]
